A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer.
Gary Middleton(University of Birmingham), John P. Neoptolemos(University of Liverpool), Jonathan Wadsley(Weston Park Cancer Centre), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), William Greenhalf(University of Liverpool), David Propper(St Bartholomew's Hospital), David Cunningham(Royal Marsden NHS Foundation Trust), Victoria Shaw(University of Liverpool), Juan W. Valle(The Christie NHS Foundation Trust), Gemma Nanson(Cancer Research UK), Trevor F. Cox(University of Liverpool), Paul J. Ross(Guy's and St Thomas' NHS Foundation Trust), Fareeda Y. Coxon(Newcastle upon Tyne Hospitals NHS Foundation Trust), Paul Silcocks(University of Liverpool), Tom Roques(Norfolk and Norwich University Hospital)
Cited by 19
Related Papers
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
|The Lancet|2017|1.9k
Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
|JAMA|2010|1.4k
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
|The Lancet Oncology|2019|1.2k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k